The Impact of Mesalazine Pill Burden on Compliance in Inflammatory Bowel Disease Patients.

ABSTRACT:

Introduction

There are a limited number of studies that have investigated mesalazine persistence and adherence using administrative/pharmacy claims data that may approximate real-world clinical practice data; therefore, the aim of this study was to compare the adherence to oral mesalazine between different groups of inflammatory bowel disease (IBD) patients in relation to the tablet strength (number of pills per day) dispensed in retail pharmacy.

Methods

This was a retrospective cohort study in French patients using the IQVIA Longitudinal Prescription Data, a patient database based on retail pharmacy claims.

Results

Of the 21,669 patients with a pharmacy claim for oral mesalazine initiated for IBD between June 2020 and April 2022, after exclusion criteria were applied

SUBMITTER: Kirchgesner J 

PROVIDER: S-EPMC12503480 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature